HMGB1: A Promising Therapeutic Target for Prostate Cancer

Abstract

High mobility group box 1 (HMGB1) was originally discovered as a chromatin-binding protein several decades ago. It is now increasingly evident that HMGB1 plays a major role in several disease conditions such as atherosclerosis, diabetes, arthritis, sepsis, and cancer. It is intriguing how deregulation of HMGB1 can result in a myriad of disease conditions. Interestingly, HMGB1 is involved in cell proliferation, angiogenesis, and metastasis during cancer progression. Furthermore, HMGB1 has been demonstrated to exert intracellular and extracellular functions, activating key oncogenic signaling pathways. This paper focuses on the role of HMGB1 in prostate cancer development and highlights the potential of HMGB1 to serve as a key target for prostate cancer treatment.

Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin

“…Targeting the HMGB proteins has shown some promise in cancer therapy, although targeting HMGB1 has been a matter of debate due to the conflict between its intracellular DNAassociated functions and extracellular cytokine functions (24). Nevertheless, HMGB1 has been shown to be a promising therapeutic target for prostate cancer (25). siRNA-mediated depletion of HMGB2 has been shown to increase chemo-and radiosensitivity of head and neck squamous cell carcinomas (26), breast cancer cells (27), and colorectal cancer cells (28).…”

Role of receptor for advanced glycation end products in the complication and progression of various types of cancers

“…This paved the way to a study in which inhibition of androgen dependent/ independent prostate tumor in mice model was observed [55]. Here we can say that gene targeting can be a promising method to achieve therapeutic effects against the complication caused by the receptor.…”

Downregulation of high mobility group protein box‑1 resensitizes ovarian cancer cells to carboplatin

“…HMGB1 was reported to serve a crucial role in numerous human diseases, including arthritis (16), sepsis (17), Alzheimer's disease (18), and cardiovascular disease (19). Additionally, HMGB1 was implicated in the progression and development of several types of cancer, including lymphoma (20), and breast (21), lung (22), liver (23), stomach (24), colon (25), prostate (26) and ovarian cancer (27). HMGB1 overexpression was revealed to be involved in the evasion of apoptosis, abnormal proliferation and metastasis of tumor cells (28).…”